UNSPSC 51401901: Rilmazafone

This classification denotes a sedative and hypnotic with the molecular formula C21H20Cl2N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU3H37T766, chemically known as 5-((2-aminoacetamido)methyl)-1-(4-chloro-2-(o-chlorobenzoyl)phenyl)-n,n-dimethyl-1h-1,2,4-triazole-3-carboxamide but generally known as rilmazafone, which bears US NIH Compound Identifier 5069. European Medicines Agency schedules Rilmazafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10315MIG.

UNSPSC 51401901 Rilmazafone (Commodity) does not align with the state and local contract opportunities currently tagged under this code. The recent solicitations—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's Request for Information on direct-to-manufacturer prescriptions, and Minnesota's MMCAP cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—center on emergency response supplies, pharmacy benefit program management, and broad pharmaceutical distribution rather than rilmazafone specifically. The code shows little relevant recent activity, and the opportunities posted under it appear to reflect broader pharmaceutical procurement categories rather than this specific benzodiazepine derivative.

The issuing bodies span state health and human services departments, county health systems, and cooperative purchasing alliances. Seminole County, Florida (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 drug deactivation systems annually through competitive bidding with quarterly deliveries to the county's community health building. Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013, April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Minnesota's MMCAP (administered by the Minnesota Department of Administration, S1070000015802, due March 26, 2026) established cooperative purchasing contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026, priced on fixed or net-pricing models. The geographic footprint spans Florida, Texas, and the upper Midwest; cooperative purchasing vehicles like MMCAP extend reach across multiple jurisdictions. Until the tagging aligns with actual procurement activity or substantive rilmazafone-specific solicitations emerge, this code carries limited pursuit priority for vendors focused on this pharmaceutical agent.